Company: BLRX
Filing Date: 2025-05-30
Form Type: 6-K
Source: 0001178913-25-002019
Chunk: 0

Company: BioLineRx Ltd.
Filing Date: 2025-05-30
Form: 6-K
Chunk 0
---
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒Form 40-F ☐ On May 30, 2025, the Registrant issued the press release which is filed as Exhibit 1to this Report on Form 6-K. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| BioLineRx Ltd. |                         |
| By:            | /s/ Philip A. Serlin    |
|                | Philip A. Serlin        |
|                | Chief Executive Officer |

Dated: May 30, 2025